drug · antibody
GP-2
Phase 3updated 3mo agoby $GLSI Greenwich LifeSciences, Inc.🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with 20 approved and 146 investigational indications.
targets
Vascular endothelial growth factor A, long form
all catalysts(0)
nothing on the calendar yet
Trials studying GP-2
News(4)
- Vaderis hauls in $152M to test an AKT-targeting drugThe startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.biopharma_dive · 9d ago
- FDA scientists question Capricor data; Legend CEO steps downCapricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…biopharma_dive · 24d ago
- Five Under 5: Top Oncology Videos for the Week of 5/3The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.onclive · 3mo ago
- Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROCAlexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.onclive · 3mo ago
Data sources
last refreshed 2m ago
Found something off?
comments(0)
5-min edit window · permanent after that